Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardia, Inc.
J&J Enters LAA Closure Market In Earnest With Coherex Buy
J&J's Biosense Webster heart-rhythm device unit has acquired privately held partner Coherex Medical, solidifying its stake in the left atrial appendage closure market that Boston Scientific currently leads.
Who's Next? Emerging LAA Closure Devices
As first-to-market in the US with a transcatheter left atrial appendage closure device, Boston Scientific has blazed a regulatory and reimbursement trail for other companies in this space and opened up a potentially billion-dollar-plus market. In this second part of our two-part series on LAAC devices, Medtech Insight reports on other companies with current and emerging LAAC devices and looks at how close they are to bringing their technology to the US market.
LAA Closure Devices At The Tipping Point
Since the FDA approval of Boston Scientific Corp.'s WATCHMAN device in March, the US market for left atrial appendage closure devices has reached a tipping point. With first-to-market advantage in the US, and a four- to five-year lead on the competition in bringing a LAAC device to the US market, BSX is well positioned to gain a strong foothold in this potentially billion dollar plus market; however, several factors will dictate market adoption of these devices in the US, including reimbursement, clinical efficacy, cost and ease of use.
Recent Developments in PFO Closure
The patent foramen ovale closure market has continued to mature in 2009, with the latest round of developments reported at the 2009 Transcatheter Cardiovascular Therapeutics meeting, recently held in San Francisco. Over 60 presentations related to PFO closure or atrial septal defect closure were presented at TCT this year, more than double the amount of PFO-related talks presented in 2008.
- Implantable Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.